Intrexon, Amneal expand relationship with second product collaboration

Utilizing Intrexon’s robust microbial-based expression system, the goal of the collaboration is to develop a consistent, scalable, and cost-effective process for the targeted complex API.

"The power of Intrexon’s synthetic biology platform in conjunction with our generic pharmaceutical development capabilities is well-suited for the advance of novel approaches to active pharmaceutical ingredients, enabling us to think beyond current production platforms," said Chintu Patel, CEO and Co-Chairman of Amneal.

"The progress achieved under our initial ECC led to this expansion of our combined efforts."

This collaboration with Amneal marks Intrexon’s third partnered program this year in which the Company is applying its microbial technology platform to produce APIs more efficiently than current methods.

By utilizing pathway development as well as strain and fermentation optimization to advance API production processes, Intrexon’s approach replaces complex, multistep chemical synthesis of APIs and also avoids resource-intensive isolation of therapeutics from animals and plants.

"This expanded partnership leverages the strengths of both organizations to develop and commercialize a high quality product for patients through a more modernized and controlled manufacturing process," said Gregory Frost, Ph.D., Senior Vice President and Head of Intrexon’s Health Sector.

"We are pleased to collaborate with Amneal on this API in a profit sharing structure given the value of this potential opportunity."

Under the terms of the agreement, Amneal will have access to all of Intrexon’s technologies and expertise to improve production of the target API. The agreement between Amneal and Intrexon provides for a sharing in the research and development costs associated with leveraging the value of their combined capabilities, as well as a sharing of the operating profits.